At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 356 enrolled
Drug / intervention
BMS-986249 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BMS-986249, Nivolumab, and 1 other intervention for Advanced Cancer. Completed, enrolled 356 participants across 45 sites in 11 countries.
Detailed Summary
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesArgentina, Australia, Canada, Chile, Finland, Germany, Italy, Poland, Romania, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartDec 2017
First PostedDec 2017
Primary CompletionNov 2024
TodayJul 2026
First PostedDec 11, 2017
Enrollment StartDec 6, 2017
Primary CompletionNov 7, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 8.6 years ago
Interventions
BMS-986249biological
Specified dose on specified days
Nivolumabbiological
Specified dose on specified days
Ipilimumabbiological
Specified dose on specified days